2025-524160-38-00RecruitingPhase 3
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Oct 2026
Brief summary (registry, in English)
To assess OS in Cohort A and Cohort B
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 134 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 12 May 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Colorectal cancer, Endometrial cancer, Gastric and esophageal cancer, Kidney cancer, Liver and biliary tract cancer, Neuroendocrine tumours, Pancreatic cancer
- EU CT number
- 2025-524160-38-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 134
- 22 sites in 10 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors or von Hippel-Lindau-related tumors who are on active treatment in a belzutifan study and want to continue.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced solid tumors or von Hippel-Lindau-related tumors.
- Earlier treatment
- Must be on active treatment in a belzutifan parent study.
Main reasons for not taking part
- An ongoing serious adverse event in the parent study, unless no longer hospitalized and clinically stable
- Currently on a dose interruption because of an adverse event in the parent study
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll
Other
- Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable
Who the study is looking for
- Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (22)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven | Leuven | Belgium | Recruiting |
| Masarykuv Onkologicky Ustav | Brno-Stred | Czechia | Recruiting |
| Fakultni Nemocnice U Sv Anny V Brne | Brno-Stred | Czechia | Recruiting |
| University Hospital Olomouc | Olomouc | Czechia | Recruiting |
| Fakultni Thomayerova nemocnice | Prague | Czechia | Recruiting |
| Universitaetsklinikum Magdeburg AöR | Magdeburg | Germany | Recruiting |
| Region Hovedstaden | Herlev | Denmark | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Recruiting |
| HUS-Yhtymae | Helsinki | Finland | Recruiting |
| Tampere University Hospital | Tampere | Finland | Recruiting |
| Centre Hospitalier Universitaire D'Angers | Angers | France | Recruiting |
| Polyclinique De Limoges | Limoges Cedex I | France | Recruiting |
| Les Hopitaux Universitaires De Strasbourg | Strasbourg Cedex 2 | France | Recruiting |
| Oncopole Claudius Regaud | Toulouse Cedex 9 | France | Recruiting |
| Institut Gustave Roussy | Villejuif | France | Recruiting |
| Orszagos Onkologiai Intezet | Budapest XII | Hungary | Recruiting |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Recruiting |
| Academisch Ziekenhuis Maastricht | Maastricht | Netherlands | Recruiting |
| Isala Klinieken Stichting | Zwolle | Netherlands | Recruiting |
| Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy | Bydgoszcz | Poland | Recruiting |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy | Warsaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.